Pentasa (Ulcerative Colitis) – Forecast and Market Analysis to 2022

Summary

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Pentasa is another mesalamine oral and topical formulations brand that is widely used for the treatment of UC. Pentasa is a microsphere formulation that consists of 5-ASA microgranules enclosed within a semi-permeable membrane composed of ethylcellulose. It is designed for controlled release that begins in the duodenum and continues into the affected regions of the lower bowel (Rasmussen et al., 1982). Pentasa is also one of the most established mesalamine products in Europe.

Scope

– Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on Pentasa including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for Pentasa for the top ten countries from 2012 to 2022.
– Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of Pentasa performance
– Obtain sales forecast for Pentasa from 2012-2022 in the top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India)

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 14
3.2 Symptoms 15
3.2.1 Quality of Life 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 22
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Pentasa (mesalamine) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 30
6.4 SWOT Analysis 30
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 34
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed UC Patients 37
7.4.2 Percent Drug-Treated Patients 38
7.4.3 General Pricing Assumptions 38
7.4.4 Individual Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in This Study 40
7.6 Primary Research - Prescriber Survey 41
7.7 About the Authors 42
7.7.1 Author 42
7.7.2 Global Head of Healthcare 43
7.8 About GlobalData 44
7.9 Disclaimer 44

1.1 List of Tables
Table 1: Genetic Factors That Confer a Predisposition to UC 13
Table 2: Typical Symptoms of UC 15
Table 3: Truelove and Witts UC Severity Index 19
Table 4: UCDAI 20
Table 5: Treatment Guidelines for UC Used in the 10MM 21
Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 22
Table 7: Leading Treatments for UC, 2014 28
Table 8: Product Profile - Pentasa 29
Table 9: Pentasa SWOT Analysis, 2014 31
Table 10: Global Sales Forecasts ($m) for Pentasa, 2012-2022 32
Table 11: Annual Cost of Therapy for 5-ASAs ($) 39
Table 12: Physicians Surveyed, By Country 41

1.2 List of Figures
Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 15
Figure 2: UC Disease Management Flowchart 25